JAKARTA - Director of Drug Registration of the Indonesian Food and Drug Supervisory Agency (BPOM) Siti Asfijah Abdoellah ensured that no one was registered in Indonesia.
"Based on BPOM searches, the four products withdrawn in Gambia, Africa, are not registered in Indonesia," said Siti Asfijah Abdoellah, quoted from ANTARA in Jakarta, Saturday, October 15.
The four medicinal products produced by Maiden Pharmaceuticals Limited, India, areselves for children, namely Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup, and Magrip N Cold Syrup.
The World Health Organization (WHO) has informed that the four products are contaminated with Dietilen Glikol (DEG) and Ethilen Glikol (EG) in Gambia, Africa.
For this reason, BPOM conducts comprehensive supervision of the premarket and postmarket of medicinal products circulating in Indonesia.
"To provide protection to the community, BPOM has set a requirement at the time of registration that all outcomes ofemphetamine for children and adults are not allowed to use dietilen glycol (DEG) and ethilen glycol (EG)," he said.
However, as a precautionary measure, BPOM is also investigating the possibility of the content of DEG and EG as contamination in other materials used as additional solvent substances.
"BPOM continues to take intensive supervision steps against related drugs and will immediately convey the results to the public," he said.
Reporting from Reuters, no less than 66 children in Gambia, West Africa, reportedly died after taking cough cough medicine containing paracetamol which was linked to a product of Maiden Pharmaceutical Ltd, India.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
